Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5726_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Preface
- •Contents
- •1.3.2 Solubility Parameters
- •1.1 Introduction
- •1.2 Types of Drug Action Theories
- •1.2.1 The Ferguson Principle
- •1.2.2 Structure and Activity
- •1.2.3 Relationship between Molecular Structure and Biological Action
- •1.3 Physicochemical Parameters and Pharmacological Activity
- •1.3.1 Introduction
- •1.3.3 Steric Parameters
- •1.4 Stereochemistry Consideration
- •1.4.1 Chirality
- •1.4.2 Stereochemistry and Drug Action
- •1.4.3 Isomers Types
- •1.5 Isosterism and Bioisosterism
- •1.5.1 Pharmacophore or Lead
- •1.5.2 Isosteres
- •1.5.3 Bioisosteres
- •1.6 Drug-Receptor Interaction
- •1.6.1 Receptor
- •1.6.2 Requirement for Agonist Activity
- •1.6.3 Receptor Families
- •1.6.4 Role of Chemical Bonding
- •1.6.5 Types of Receptors
- •1.7 Prodrugs
- •1.7.1 Introduction
- •1.7.2 Concept of Prodrug
- •1.7.3 Prodrugs are Designed for the Following Purposes
- •1.7.4 Classification of Prodrugs
- •Exercise
- •Autonomic Nervous System
- •2.1 Introduction
- •2.2 Cholinergic Drugs
- •2.2.1 Definition
- •2.2.2 Cholinergic Receptors
- •2.2.3 Biosynthesis of Ach
- •2.2.4 Classification
- •2.2.5. Action of Cholinesterase Inhibitors
- •2.2.6 Structural Activity Relationship (SAR) of Musarinic Agonist/Cholinomimetics
- •2.2.7 Cholinomimetic Agents
- •2.2.9 Classification of Anticholinergic Agents
- •2.2.10 Structural Activity Relationship (SAR) of Anticholinergic Agent
- •2.2.11 Anticholinergic Agent
- •2.2.12 Newer Drug
- •2.3 Adrenergic Agents
- •2.3.1 Introduction
- •2.3.2 Mechanism of Action
- •2.3.3 Biosynthesis of Catecholamines
- •2.3.4 Pharmacological Action
- •2.3.5 Adrenergic
- •2.3.6 Classification
- •2.3.7 SAR of Phenylethanolamine Derivatives/Direct Acting Agonist
- •2.3.8 SAR of Indirect Acting Agonist/Arylethylamine Derivatives
- •2.3.9 Adrenergic Agents
- •2.3.10 Newer Drugs
- •Exercise
- •3.1 Introduction
- •3.2 Ideal Characteristics of General Anaesthetics
- •3.4 Concepts of Mechanism of Anaesthesia
- •3.5 Minimum Alveolar Concentration (MAC)
- •3.6 Stages of Anaesthesia
- •3.7 Classification of General Anaesthesia
- •3.8 Receptors Involved in the Mechanism
- •3.9 Stereochemistry of Volatile Anaesthetics
- •3.10 Toxicity of Fluorinated General Anaesthetics
- •3.11 General Anaesthetics Agents
- •3.12 Newer Agents
- •Exercise
- •4.1 Introduction
- •4.2 Methods of Administration
- •4.3 Classification of Local Anaesthetics
- •4.4 Mechanism of Action of Local Anaesthetics
- •4.6 Local Anaesthetic Agents
- •4.7 Newer Agents
- •Exercise
- •5.1 Introduction
- •5.3 Classification of Sedative and Hypnotics
- •5.3.1 Barbiturates
- •5.3.2 Benzodiazepines
- •5.3.3 Halogenated Sedative and Hypnotics
- •5.3.4 Heterocyclic Sedative and Hypnotics
- •5.3.5 Miscellaneous Sedative and Hypnotics
- •5.4 Mechanism of Action
- •5.5 Barbiturates
- •5.5.1 General Synthetic Approach of Sedative and Hypnotics
- •5.6 SAR of (Barbiturates) Sedative and Hypnotics
- •5.7 Benzodiazepines
- •6.7 Morphines and Derivatives
- •5.8 SAR of Benzodiazepines
- •5.9 Heterocyclic Sedative and Hypnotics
- •5.10 Halogenated Sedative and Hypnotics
- •5.11 Recent Development of Sedative and Hypnotics
- •Exercise
- •6.1 Introduction
- •6.2 Opioid Receptors
- •6.3 Opioid Peptides
- •6.4 Classification
- •6.5 Mechanism of Action (Signal Transduction)
- •6.6 Central Side Effects of Opioid Analgesics
- •6.8 SAR of Morphines Derivatives
- •6.9 Piperidine Derivatives
- •6.10 SAR of Piperidines Derivatives
- •6.11 Diphenyl Haptanones Derivatives (Acyclic Analgesics)
- •6.12 SAR of Diphenyl Haptanone Derivatives
- •6.13 Benzazocin Derivatives/Morphan Derivatives
- •6.14 Narcotics Antagonists/Opioid Antagonists
- •6.15 Newer Drugs
- •6.16 Antitussive Agents
- •Exercise
- •7.1 Introduction
- •7.2 Classification of Epilepsy
- •7.3 Seizure Initiation and Propagation
- •7.4 Receptors Involved in the Mechanism
- •7.5. Classification of Antiepileptic Agnents
- •7.5.1 Ureid Derivatives/First Generation Antiepileptic Agents
- •7.5.2 Benzodiazepines
- •7.5.3 Urea and MonoAcyl Urea-Derivatives/Iminostilbenes
- •7.5.4 Miscellaneous Agents
- •7.6 Hydantoins Agents
- •7.7 Oxazolidinediones Agents
- •7.8 Succinimides Agents
- •7.9 Iminostilbens Agents
- •7.10 Aliphatic Acid Agent
- •7.11 Second Generation Antiepileptic Drugs
- •7.12 Other Miscellaneous Antiepileptic Agents
- •7.13 Models Requirements for Antiepileptic Agents/SAR
- •7.14 Newer Drugs Development
- •Exercise
- •8.1 Introduction
- •8.2 Etiology of Parkinson
- •8.3 Initiation of Therapy
- •8.4 Classification of Antiparkinsonism Agents
- •8.4.1 Dopaninergic Treatment
- •8.4.2 Agents Action on Nondopaminergic System
- •8.5 Dopaminergic Agents
- •8.6 Non-Dopaminergic Agents
- •8.7.1 Conformational Aspects
- •8.7.2 PKa Aspects
- •Exercise
- •9.1 Introduction
- •9.2 Clinical Uses of CNS Stimulants
- •9.3 Classification
- •9.4 Mechanism of Action
- •9.5 CNS Stimulants Agents
- •9.5.1 Amphetamine Related Agents
- •9.5.2 SAR or Structural Requirements of Amphetamines
- •9.5.3 Xanthine Alkaloids
- •9.5.4 Cocaine Related CNS stimulating Agents
- •9.5.5 Miscellaneous CNS Stimulants Agents
- •9.5.6 Newer Agents
- •9.6 Metabolic Patterns of Some CNS Stimulants Agents
- •9.7 Analeptics or Respiratory Stimulants
- •Exercise
- •10.1 Introduction
- •10.2 Causes of Schizophrenia
- •10.2.1 Adverse Effects
- •10.3 Antipsychotic Agents
- •10.3.1 Mechanism of Action
- •10.4 Classification
- •10.5 Tricyclic Neuroleptics/Phenothiazines
- •10.5.1 Phenothiazines Structure and Structure Activity Relationship
- •10.5.2 Specific Derivatives
- •10.6 Thioxanthene Derivatives
- •10.7 Dibenzoxazepine and Dibenzdiazepine Derivatives
- •10.8.1 SAR of Butyrophenones
- •10.8.2 Butyrophenones Agents
- •10.9 Benzamides Derivatives
- •10.9.1 Structure Activity Relationship of Benzamides
- •10.9.2 Specific Derivatives
- •10.10 Dihydroindolone Derivative
- •10.11 Diphenylbutylpiperidine Derivatives
- •10.12 Miscellaneous Agents
- •10.13 Newer Agents
- •Exercise
- •11.1 Introduction
- •11.2 Management of Depression
- •11.3 Classification
- •11.4 Tricyclic Antidepressants
- •11.4.1 Mechanism of Action
- •11.4.2 Structural Activity Relationship (SAR) of Tricyclic Antidepressants (TCAs)
- •11.4.3 Metabolic Pattern of Tricyclic Antidepressants
- •11.4.4 Specific Drugs
- •11.6 Specific Drugs
- •11.7 Selective Serotonine Reuptake Inhibitors (SSRI)
- •11.7.1 Mechanism of Action
- •11.7.2 Structure Activity Relationship (SAR) of (SSRIs)
- •11.7.3 Specific Drugs
- •11.8 Newer Atypical Antidepressants
- •11.8.1 Specific Drugs
- •11.9 Newer Agents
- •Exercise
- •12.1 Introduction
- •12.2 Causes of Anxiety
- •12.2.1 Receptor Involve
- •12.3 Classification
- •12.4 Benzodiazepines
- •12.4.1 Mechanism of Action
- •12.4.2 Metabolic Pattern
- •12.5 Structure Activity Relationship (SAR) of Benzodiazepines
- •12.6 Benzodiazepines Derivatives (Specific Drugs)
- •12.7 Non-benzodiazepine Derivatives (Specific Drugs)
- •12.8 Newer Agents
- •Exercise
- •13.1 Introduction
- •13.2 Mechanism of Action
- •13.3 Classification
- •13.4 Specific Derivatives
- •13.4.1 Glycerol Monoethers Derivatives
- •13.4.2 Alkanediols Derivatives
- •13.4.3 Benzazole Derivative
- •13.4.4 Imidazolin Derivative
- •13.4.5 Miscellaneous Agents
- •13.5 Newer Agents
- •Exercise
- •14.1 Introduction
- •14.2 Mechanism of Action
- •14.3 Classification
- •14.4 Non-depolarizing Muscle Relaxants
- •14.5 Structural Activity Relationship of Aminosteroids NMB Agents
- •14.6 SAR of Tetrahydroisoquinoline Derivatives
- •14.7 Depolarizing Muscle Relaxants (DPR)
- •14.8 SAR of Depolarizing Muscle Relaxants
- •14.9 Newer Agents
- •Exercise
- •15.1 Introduction
- •15.2 Nomenclature of Heterocyclic Compounds
- •15.3 Naming of Heterocyclic Rings
- •15.4 Nomenclature of Fused Ring System
- •Exercise
- •References
- •Index

Neuromuscular Blocking Agents 225
14.9 NEWER AGENTS
1. Atracurium Besylate: 2,2’-(3,11-dioxo-4,10-dioxatridecylene)-bis-[6,7-dimethoxy-benzyl)-2-
methyl-1,2,3,4 tetra hydro Isoquinolinum]. Dibenzene sulfonate is the new series of competitive
neuromuscular blocking agents. Atracurium besylate is used in anaesthesiology for muscle relaxants.
N
H
N
HCO
3
OCH
3
+
CH
3
OCH
3
OCH
3
OCH
3
OCH
3
+
OCH
3
HCO
3
O
(CH )
25
O
O
O
HC
3
Fig. 14.20
2. Mivacurium:
Mivacurium is a short acting non-depolarizing muscle relaxant (NDPMR) with benzyl-isoquinoline
structure. Neuromuscular blocking activity may be prolonged due to low plasma choline sterase
activity.
HCO
3
N
+
HCO
3
H
(CH ) — OC(CH ) — CH CH (CH ) — CO — O — (CH )
23 22 2 22 23
HCO
3
HCO
3
OCH
3
CH
3
+
N
OCH
3
OCH
3
OCH
3
OCH
3
OCH
3
HC
3
Fig. 14.21
2, 2-(1,8–dioxo-4-dtene 1,8-diyl)-bis-(oxy-3,1-Propanediyl)-bis (1,2,3,4-tetrahydro-6,7-dimethoxy-
2-methyl-1-(3,4,5-trimethoxyphenyl)-methyl] isoquinoinium) dichloride.
C. Lee (2001) “British-J. of Anaesthesia, 87(5): 755-69(2001) Structure, conformation and action of neuromuscular
blocking drugs.

226 A Textbook of Medicinal Chemistry
EXERCISE
1. Define neuromuscular blocking agents.
2. Explain non-depolarizing and depolarizing muscle relaxant with their structures.
3. Classify NMB agents and give their mechanism of action.
4. Explain aminosteroids derivatives. Give the SAR of aminosteroids agents.
5. Write the synthesis of the following drugs with MOA and uses
1. Pancuronium
2. Gallamine
3. Hexa fluorinium
4. Succinyl choline
6. Write the SAR on depolarizing muscles relaxants.
7. Explain 10 atoms roles in NMB agents.
8. Write in details of tetrahydro isoquino lines derivatives.

General Considerations of Heterocyclic Chemistry Concept 227
15
General Considerations of
Heterocyclic Chemistry Concept
15.1 INTRODUCTION
Concept of heterocyclic chemistry in medicinal csompounds is that which possesses the cyclic
ring structure, having at least two different kinds of atoms in the ring. The most common type of
atoms include nitrogen, oxygen and sulphur heteroatoms that contains largely carbon atoms. Apart
from that, many atom elements including even bromine also is part of heterocyclic chemistry.
Heterocyclic compounds are widely arranged in nature and are essential for life in various ways.
They can be aliphatic or aromatic in nature depending upon the distribution of electronic constitution.
In this chapter a brief introduction is detailed to the simple types of three-, five- and six-
membered heterocyclic system and their naming.
15.2 NOMENCLATURE OF HETEROCYCLIC COMPOUNDS
According to Systemic Nomenclature System (Hantzsch-Widman System)
According to this system, heterocyclic compounds are recognized by their trival names.
Examples:
N
O
S
N
H
N
N
N
N
O
N
N
Pyrrole Furan Thiophene Pyrazole Imidazole Furazan
a
a a

228 A Textbook of Medicinal Chemistry
Symbols represents
a → 1H Tautomer
b → 2H Tautomer
c → 9H Tautomer
d → 4H Tautomer
e → 10H Tautomer
f → Saturated heterocyclic rings
Fig. 15.1
15.3 NAMING OF HETEROCYCLIC RINGS
Prefix
+
Stem
Heteroatoms
Number
Position
Ring size
Saturation
1
2
3
2
1
Fig. 15.2
Table 15.1: Common prefixes
Element Prefix
Oxygen Oxa
Sulphur Thia
N
H
Carbazole
Phenazine
Phenothiazine
Phenenthridine
Pyrrolidine
f
Piperidine
Piperazine
Chroman
e
O
H
N
Morpholine
O
f
f
f
f
N
H
NH
N
H
N
N
H
N
Indole Isoindole Indazole Purin Indolizine
Quinoline Isoquinoline Quinazoline Pteridine Quinalizine
b
a
a
c
d
N
N
N
N
N
N
N
N
N N
N
N
N
N
N
H
S
N
H
N
N
H
N
H
N
H

General Considerations of Heterocyclic Chemistry Concept 229
Selenium Selena
Nitrogen Az a
Tellurium Tellura
Phosphorus Phospha
Arsenic Arsa
Silicon Sila
Germanium Germa
Boron Bora
Table 2:
Stem Ring Size Unsaturated Ring Saturated Ring
3 irene
(a)
irane
(b)
4 ete etane
(b)
5 ole olane
(b)
6 ine© inane
(d)
7 epine epane
8 ocine ocane
9 onine onane
10 ecine ecane
SYMBOLS REPRESENT:-
a → Three-member ring contain nitrogen
b → Saturated ring containing nitrogen
c → ‘inine’ used with some Phosphorous, arsenic and boron heterocycles
d → ‘ane’ is used if immediately preceded by the Prefixes ‘ox’, ‘thi’, selen.
Examples:
O
O
N
N
ON
Thirene
Oxirane
1, 3-diazete
1, 2-Oxazetidine
O
O
S
1, 3-Dioxolane 1,2,4 Triazine
Thiepene
Azocine
N
N
N
N
H
Fig. 15.3

230 A Textbook of Medicinal Chemistry
15.4 NOMENCLATURE OF FUSED RING SYSTEM
Fused ring system involving the benzene ring may be fused on to the carbon atoms of each of these
three heterocyclic compounds in two different positions. Six possible structures are illustrated
below:
N
X
X
Indole X = NH Isoindole Indolizine
Benzofuran X = O Isobenzofuran
Benzo[b] thiophene X= S Benzo[c]thiophene
Fig. 15.4
15.5 RULES OF NOMENCLATURE OF FUSED RING SYSTEM:
(1) Select prefix (O)
(2) Select base component
Example
Benzoxazole
O
N
Fig. 15.5
Base Component:
1. Choose, one ring containing ‘N’
Example
Benzoxazole
O
N
Fig. 15.6
2. Prefer than oxa, thia, aza
S
O
Thieno [ ] furane
Fig. 15.7

General Considerations of Heterocyclic Chemistry Concept 231
3. Select one consisting two or more rings
N
H
NH
Pyrrolo [ ] indole
4. Select the larger ring if two rings of different size
N
H
N
Pyrrolo [ ] Pyridine
5. Select the most heteroatom containing ring
Pyrrolo [ ] pyrrazole
H
N
N
H
N
6. If same number of heteroatoms are present, choose with priority oxa > thia > aza with
higher electronegativity
O
N
N
H
N
Imidazo [ ] oxazole
7. If the same number of heteroatoms are present of oxa, thia, aza then select with lower
numbering
Oxazola [ ] isoxazole
Imidazo [ ] Pyrrazola
O
N
N
O
N
N
N
H
H
N

232 A Textbook of Medicinal Chemistry
8. Another aspect to indicate the fusion by the given letter symbols to the base components and
numbers to the prefix (in same direction)
Example
O
N
d
c
b
a
O
O
1
2
3
4
5
Oxazolo[5,4-d]isoxazole
EXERCISE
1. Give a brief note on heterocyclic chemistry
2. Discuss nomenclature of heterocyclic compounds.
3. Write about Hantzsch-Widman system.
4. Write the name of tricyclic heterocyclic compounds
5. Discuss with examples of nomenclature of fused ring system.

General Considerations of Heterocyclic Chemistry Concept 233
References
1. Abraham. D. J. (Ed), Burger’s Medicinal Chemistry. Vol. 6, Nervous system agents, Wiley,
New York, edition 6, 2003.
2. Wilson and Gisvold’s Textbook of Organic Medicinal and Pharmaceuticals Chemistry,
Block, J. H. and Beal J. M. Jr (Editors), 11
th
edition, 2004.
3. Foye’s Principles of Medicinal Chemistry, Williams, D. A. and Lemke, L. T. (Editors), 5
th
ed., 2002.
4. Elsevier’s Synthesis of Essential Drugs, Vardanyan R. and Hruby V-(Editors), First edition,
2006.
5. The principles of Heterocyclic Chemistry, Katrifzky. A. R. and Langowski. M (Editors),
Pharma-Med Press, 2009.
6. An Introduction to the Chemistry of Heterocyclic compounds, Acheson. R. M. (Editor),
Third edition, (Wiley student Edition), 2008.
7. Essential of Medicinal Chemistry, Korolkovas A. (Editor), second edition (Weley India Edition),
2008.
8. Elsevier’s Comprehensive Medicinal Chemistry, Hansch. C, Sanmes, P.G. and Taylor. J. B.
(Editors), Volume 1 (Pergamon Press), 2005.
9. Name reaction: a collection of detailed reaction mechanism, Li. J. J. (Ed.), 2
nd
edition (Springer
International edition), 2004.
10. Medicinal Chemistry, A Molecular and Biochemical Approach, Nogrady. N, Weaver D. F.
(Editors), 3
rd
edition (Oxford University Press), 2005.
11. The Textbook of Pharmaceutical Medicine, Grijjin J. P and Grady J. O. (Editors), 5
th
(Blackwell
Publishing), New Age International Publishers), 2006.
12. Elsevier’s The Practice of Medicinal Chemistry, Wermuth C. G, (Editor), 2
nd
edition (Academic
Press), 2004.
13. Principles of Medicinal Chemistry including Proteomics, Ranganathan S and Suresh, A. J,
CBS Publishers and Distributors, 2011.
14. Chemistry for Pharmacy student’s General, Organic and Natural Product Chemistry, Sarker,
S.D. and Nahar, L (Editors), John Wiley and Sons Ltd., 2007.
15. Harrison’s Principles of Internal Medicine, Braunwald E, Fauci. A.S., Kasper, L. D (Editors),
2
nd
Volume, 17
th
edition (McGraw-Hill), 2008.

Соседние файлы в папке Библиотека им академика М.И. Перельмана
